iBlend™ is Highly Rated in Clinical Trial and Significantly Reduced Cravings for Usual Brand Cigarettes

Contributed by: Business Wire

Logo

Tags

Retail

Health

Tobacco

Clinical Trials

Research

Science

iBlend

More Like This

Cabbacis Common Stock Listed on OTCQB Venture Market

Cabbacis Announces IPO Via Regulation A

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

PR Newswire associated0

SpectrumLeaf Launches COCO: A Game-Changer in the Nicotine Pouch Market

(Photo: Business Wire)

ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a Clinical Trial Evaluating Nantheia™ ATL5 for Smoking Cessation

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

First Cannabis full-spectrum product, manufactured in Brazil by Ease Labs, is approved by the local Health Regulatory Agency